Posterior reversible encephalopathy syndrome (PRES) is a rare and generally reversible neurological disorder that was first described in the field of hematopoietic stem cell transplantation (HSCT) by Sloane et al. 1 To date, its pathogenesis remains unclear but seems to be related to dysregulation of cerebral blood flow with endothelial dysfunction, resulting in cerebral hypoperfusion and a brain capillary leak syndrome. This syndrome is characterized by headaches, visual disturbances, seizures and an altered state of consciousness. 2 It is mostly associated with radiological hypodensities in the posterior white matter, most frequently in the parietal and occipital lobes. 3 PRES can mimic many other neurological conditions such as autoimmune encephalopathy, central nervous system vasculitis, ischemic stroke, toxi-metabolic encephalopathy and demyelinating disorders. Because there are currently no specific diagnostic criteria, clinical findings and neuroimaging are essential to diagnose PRES promptly and initiate the appropriate treatment.
We report an unusual case of a multiple myeloma patient who presented with clinical manifestations compatible with PRES, 7 months after allogeneic HSCT while taking tacrolimus for treatment of grade III acute GvHD and bortezomib to prevent myeloma relapse. On autopsy, the patient was found to have disseminated adenovirus vascular endothelial infection.
The patient was a 60-year-old male who presented with progressive back pain in 2014. Investigations revealed normocytic anemia, acute renal failure, hypercalcemia and multiple bone lytic lesions, including D11-D12 vertebral compression fractures. β2 microglobulin and LDH concentrations were increased. Serum protein electrophoresis and immunofixation were uninformative but serum free light chain ratio was significantly increased with a kappa free light chain level of 10 700 mg/L. Bone marrow biopsy revealed 68% of plasma cells which were negative for high-risk cytogenetic features by fluorescent in situ hybridization, including del17p, t(4;14), t(14;16), t(14;20), del1p and 1q gain. A diagnosis of de novo kappa light chain multiple myeloma Durie-Salmon IIIB, international staging system (ISS) stage III and revised ISS II was therefore made.
The patient received a triplet bortezomib-based induction treatment (in combination with thalidomide and dexamethasone, VTD) and achieved a CR after 4 cycles. Following autologous stem cell collection, he subsequently received high-dose melphalan (200 mg/m 2 ) followed by autologous HSCT (CD34 + cell graft content: 6.6 × 10 6 /kg), maintaining a CR. After informed consent, the patient received an outpatient 8/8 matched sibling allogeneic HSCT after a conditioning regimen of fludarabine and cyclophosphamide; acute GvHD prophylaxis consisted of mycophenolate mofetil (MMF) and tacrolimus, as previously reported. 4 Bortezomib consolidation (1.3 mg/m 2 every 2 weeks for 26 planned doses) was started on day +120 after allogeneic HSCT as part of an institutional approved experimental protocol aimed at decreasing both relapse and chronic GVHD after tandem transplant (Clinicaltrial.gov NCT02308280).
On day +125 after allogeneic HSCT, the patient was admitted because of diarrhea of more than 1500 mL per day. Investigations for enteric pathogens, including adenovirus, rotavirus, calicivirus, clostridium difficile and other pathogenic bacteria, as well as parasites, were negative. A computerized axial tomography (CT) scan of the abdomen showed inflammation of the last 60 cm of the ileum. A rectosigmoidoscopy with biopsies revealed histologic findings compatible with pathologic grade I acute GvHD with absence of viral inclusions. Clinical presentation was therefore compatible with acute GvHD grade III with isolated intestinal involvement. Bortezomib was temporarily discontinued; the patient's condition gradually improved after receiving i.v. methylprednisolone followed by oral prednisone, tacrolimus, MMF and beclomethasone. He left the hospital after 18 days.
On day +204, while on prednisone 15 mg daily and bortezomib as per protocol, the patient was rehospitalized with chills, suprapubic pain, hematuria and resurgence of diarrhea. Thorough investigation revealed enterococcal pyelonephritis, hemorrhagic cystitis with presence of adenovirus in the urine culture and relapsed intestinal GvHD. Bortezomib administration was discontinued and broad-spectrum i.v. antibiotics with vigorous hydration were started, leading to prompt resolution of cystitis symptoms. In addition, prednisone was increased to 50 mg daily and tacrolimus adjusted to maintain levels between 8-12 ng/mL. On day +217, despite sub-therapeutic tacrolimus levels, the patient became rapidly delirious and confused. Tacrolimus was immediately discontinued and blood pressure tightly controlled. A nonenhanced head CT scan revealed diffuse hypodensities involving bilateral parieto-occipital regions without any mass effect or hemorrhage (Figure 1 ). These findings were highly suggestive of PRES in the clinical context and further imaging or a lumbar puncture were not considered necessary. It was then decided that magnetic resonance imaging (MRI) was to be performed if the patient's clinical condition did not improve after tacrolimus discontinuation. Despite appropriate care, the patient became comatose, hypotensive and oliguric two days later, followed by the emergence of liver failure and diffuse intravascular coagulation. At that time, a high adenovirus load was found in the blood (3.63 × 10 8 copies per mL) by PCR but cidofovir was not initiated due to a rapidly rising creatinine level. Despite transfer to the intensive care unit and aggressive supportive care, the patient died 24 h later.
Autopsy analysis of different organs revealed histopathologic modifications consisting of diffuse ischemic changes of the small bowel, focal hemorrhages in the renal hilum as well as acute microscopic foci of cerebral cortical necrosis. Histologic identification of viral particles was inconclusive, but immunohistochemical antiadenoviral stains (Vetana, USA) demonstrated abundant disseminated viral inclusions limited to endothelial cells, while epithelial cells were exempt of any staining in the kidneys, lungs, liver, intestine, bladder and brain (Figure 2a) . Evaluation by electron microscopy confirmed the presence of characteristic viral particles in the nuclei of endothelial cells compatible with diffuse adenovirus endotheliitis in all organs mentioned above (Figure 2b) .
Adenovirus infection occurs in 5-21% of patients after allogeneic HSCT. 5 Adenoviruses most commonly infect human epithelial cells and cause a wide range of clinical manifestations such as hemorrhagic cystitis, pneumonia, hepatitis, colitis, encephalitis and disseminated disease, leading to mortality rates ranging from 18 to 60%. In humans, the documentation of endothelial damage is scarce, notably because autopsy is not always performed. One pediatric haplo-identical HSCT complicated with lethal multi-organ failure has been reported with specific endothelial damage by adenoviral particles along coronary vessels. 6 In contrast, local and systemic vasculitis has been described in animals such as mule deer in the United States, causing hemorrhagic disease. Evidence of endothelial intranuclear inclusions and endothelial adenovirus particles in vessels were found by EM in these animals. 7 To the best of our knowledge, a case of disseminated adenovirus endotheliitis presenting with clinical and radiological manifestations of PRES has never been described in an adult allogeneic HSCT recipient. Most cases of PRES occurring after allogeneic HSCT are associated with immunosuppressive medication, most notably calcineurin inhibitors (cyclosporine, tacrolimus). The mechanisms of central nervous system toxicity associated with tacrolimus remain poorly understood but clinical manifestations are usually reversible after discontinuation of this medication. 8 We hypothesize that cerebral endothelial involvement and dysfunction caused by adenovirus infection led to a clinical picture mimicking PRES by creating foci of vasogenic edema and acute cortical necrosis. Potential risk factors for disseminated adenovirus infection in this patient include the immune deficiency associated with grade III acute GvHD, the simultaneous use of several immunosuppressants (prednisone, MMF, tacrolimus) to control relapsed acute GvHD and quite possibly, the use of bortezomib for consolidation after allogeneic HSCT. Bortezomib has been shown to have immunosuppressive properties 9, 10 and its use has been associated with increased rates of herpes zoster but rarely with adenovirus infections. [11] [12] [13] To date, no other case of systemic adenovirus infection has been observed in 23 similarly treated patients currently enrolled in our study thus far. 14 In summary, we report a case of widely disseminated adenovirus endotheliitis with cerebral involvement in an adult patient who underwent tandem autologous-allogeneic HSCT and presented clinically and radiologically as a PRES while on bortezomib and other immunosuppressants. Adenovirus endotheliitis should be considered in the differential diagnosis of immunocompromised patients presenting with nonspecific neurological symptoms or alterations of their state of consciousness. Appropriate investigation, including brain CT scan, MRI and adenovirus load assessment by blood PCR could allow prompter initiation of cidofovir or brincidofovir 15 and potentially improve clinical outcome. Also, considering drug therapy limited effectiveness in refractory infections and toxicity especially in renal failure, adoptive immunotherapy with adenovirus-specific cytotoxic T lymphocytes is promising. Finally, prospective monitoring of adenovirus by PCR should be considered in allogeneic transplant recipients receiving a proteasome inhibitor such as bortezomib, carfilzomib or ixazomib and who develop acute GvHD requiring systemic immunosuppressants.
